Holen Sie sich die Stockscreener-App
0.4051
4.00%
-0.0169
Schlusskurs vom Vortag:
$0.422
Offen:
$0.4093
24-Stunden-Volumen:
428.19K
Relative Volume:
0.08
Marktkapitalisierung:
$6.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.21M
KGV:
-7.3923
EPS:
-0.0548
Netto-Cashflow:
-
1W Leistung:
-27.66%
1M Leistung:
-31.34%
6M Leistung:
-96.27%
1J Leistung:
-99.86%
1-Tages-Spanne:
$0.3909
$0.437
1-Wochen-Bereich:
$0.37
$0.5697
52-Wochen-Spanne:
$0.37
$328.00
Conduit Pharmaceuticals Inc Stock (CDT) Company Profile
Firmenname
Conduit Pharmaceuticals Inc
Sektor
Branche
Telefon
(646) 491 9132
Adresse
4851 TAMIAMI TRAIL NORTH, NAPLES
Vergleichen Sie CDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDT
Conduit Pharmaceuticals Inc
|
0.4048 | 6.33M | 0 | -4.21M | 0 | -0.0548 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.54 | 130.98B | 11.10B | -988.90M | -978.00M | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.62 | 64.65B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
554.30 | 39.39B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.72 | 34.32B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.49 | 28.03B | 3.81B | -644.79M | -669.77M | -6.24 |
Conduit Pharmaceuticals Inc Aktie (CDT) Neueste Nachrichten
Conduit Pharmaceuticals Files New Patent For AZD5904 - marketscreener.com
In 2025, Will Conduit Pharmaceuticals Inc (NASDAQ: CDT) Be Bullish Or Bearish? - Stocksregister
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset - The Manila Times
Conduit Pharmaceuticals Files Composition of Matter Patent for Azd5904 Creating Robust Ip Foundation for Pipeline Asset - marketscreener.com
Conduit Pharmaceuticals Approves Reverse Stock Split Amendments - TipRanks
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Shares Acquired by Geode Capital Management LLC - Defense World
Conduit Pharmaceuticals Inc (CDT)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Short Interest in Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Increases By 98.5% - Defense World
Keeping an Eye on Conduit Pharmaceuticals Inc (CDT) After Insider Trading Activity - knoxdaily.com
Conduit Pharmaceuticals Inc (CDT)’s Day in Review: Closing at 0.56, Up by 4.07 - DWinneX
Investor’s Delight: Conduit Pharmaceuticals Inc (CDT) Closes Weak at 0.65, Down -5.79 - DWinneX
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Price Down 2.9% – Time to Sell? - Defense World
What Do Wall Street Analysts Think About Conduit Pharmaceuticals Inc (NASDAQ: CDT) Stock? - Stocksregister
Conduit Pharmaceuticals files to sell 2.1M shares of common stock for holders - MSN
Conduit Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
Are Conduit Pharmaceuticals Inc (CDT) shares a good deal now? - uspostnews.com
Market Resilience: Conduit Pharmaceuticals Inc (CDT) Finishes Weak at 0.62, Down -20.51 - DWinneX
CDT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
CDTConduit Pharms Latest Stock News & Market Updates - Stock Titan
Conduit Pharmaceuticals Announces Leadership Changes - marketscreener.com
Serial Entrepreneur with $7B+ Exit Track Record Takes CEO Role at Conduit Pharma - Stock Titan
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener
Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program - The Manila Times
Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan
Conduit Pharmaceuticals expands partnership with Sarborg - MSN
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization - The Manila Times
Machine Learning Deal: How Conduit Pharma Plans to Revolutionize Drug Development - Stock Titan
Analyzing Conduit Pharmaceuticals (CDT) and Its Competitors - Defense World
Conduit Pharmaceuticals meets Nasdaq listing standards By Investing.com - Investing.com Australia
Conduit Pharmaceuticals meets Nasdaq listing standards - Investing.com
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - The Manila Times
Major Patent Win: Conduit's Autoimmune Drug Gets 20-Year Market Protection - Stock Titan
Conduit Pharmaceuticals Inc. (CDT) reports earnings - Quartz
CONDUIT PHARMACEUTICALS INC. SEC 10-K Report - TradingView
CONDUIT PHARMACEUTICALS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Conduit Pharma Highlights Progress In Lupus Studies, Phase II Trial For AZD1656 - Nasdaq
Conduit Pharmaceuticals progresses in autoimmune drug studies By Investing.com - Investing.com Australia
Conduit Pharmaceuticals progresses in autoimmune drug studies - Investing.com
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 - The Manila Times
Conduit Pharmaceuticals Reports Significant R&D Advancements in Lupus Studies and Pipeline Development - Nasdaq
Conduit's Triple-Drug Pipeline Shows Promise for Lupus TreatmentMajor R&D Breakthrough - StockTitan
A closer look at Conduit Pharmaceuticals Inc (CDT)’s stock price trends - uspostnews.com
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - The AM Reporter
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer - MarketScreener
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - StockTitan
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Finanzdaten der Conduit Pharmaceuticals Inc-Aktie (CDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
2.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):